Jane A. Gross Purchases 3,750 Shares of Atyr PHARMA INC (NASDAQ:ATYR) Stock

Atyr PHARMA INC (NASDAQ:ATYR) Director Jane A. Gross purchased 3,750 shares of the stock in a transaction on Monday, March 17th. The shares were acquired at an average cost of $4.00 per share, with a total value of $15,000.00. Following the transaction, the director now directly owns 9,750 shares in the company, valued at $39,000. The trade was a 62.50 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Atyr PHARMA Stock Down 3.5 %

Shares of NASDAQ:ATYR opened at $3.87 on Wednesday. Atyr PHARMA INC has a 52-week low of $1.42 and a 52-week high of $4.66. The firm has a market capitalization of $324.86 million, a P/E ratio of -4.12 and a beta of 0.98. The stock has a 50 day moving average price of $3.65 and a 200-day moving average price of $3.11. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. As a group, equities research analysts anticipate that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ATYR has been the subject of a number of recent analyst reports. Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a research report on Tuesday, February 18th. Leerink Partners initiated coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an “outperform” rating and a $16.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Friday, March 14th. Finally, Cantor Fitzgerald assumed coverage on Atyr PHARMA in a research report on Monday, January 6th. They issued an “overweight” rating for the company. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $18.60.

Institutional Trading of Atyr PHARMA

Several hedge funds and other institutional investors have recently made changes to their positions in ATYR. JPMorgan Chase & Co. grew its stake in shares of Atyr PHARMA by 52.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock worth $55,000 after buying an additional 10,754 shares during the last quarter. Kingswood Wealth Advisors LLC purchased a new stake in shares of Atyr PHARMA in the 4th quarter worth approximately $170,000. Alterna Wealth Management Inc. purchased a new stake in shares of Atyr PHARMA in the 4th quarter worth approximately $36,000. D.A. Davidson & CO. purchased a new stake in shares of Atyr PHARMA in the 4th quarter worth approximately $141,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Atyr PHARMA in the 4th quarter worth approximately $144,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.